Otsuka Pharmaceutical Co., Ltd. / Jnana Therapeutics Inc.

Phenylketonuria (PKU) and autoimmune disease pipeline

17K US cases/yr · $650M Global PKU pharmacotherapy market 2024 (Kuvan + Palynziq combined) · 394 Palynziq 2024 global net sales (USD MM, BioMarin benchmark for PKU pharmacotherapy)

Disease Overview

Phenylketonuria is a rare autosomal recessive inborn error of amino acid metabolism caused by deficiency of phenylalanine hydroxylase (PAH), resulting in toxic accumulation of phenylalanine (Phe) that causes intellectual disability, seizures, behavioral disturbances, and microcephaly if untreated. The National PKU Alliance and NIH estimate US prevalence at approximately 16,500 patients (1 in 10,000-15,000 live births). All 50 states screen newborns, so essentially all US PKU patients are diagnosed at birth. Current standard of care is lifelong dietary Phe restriction (medical formula plus low-protein foods) which is difficult to maintain, particularly in adolescents and adults, leading to loss of metabolic control. Pharmacotherapy options are limited: Kuvan (sapropterin dihydrochloride, BioMarin) — oral BH4 cofactor, effective only in the ~30-50% of patients with responsive PAH variants; Palynziq (pegvaliase, BioMarin) — injectable PAL enzyme substitution, high anti-drug antibody burden requiring complex titration and REMS. Both BioMarin products together generated approximately $650M in 2024. JNT-517 is a first-in-class oral small-molecule allosteric inhibitor of SLC6A19, the intestinal and renal amino acid transporter responsible for Phe reabsorption; by blocking reabsorption, it enables urinary Phe excretion regardless of PAH genotype, positioning it as genotype-agnostic Phe reduction without dietary restriction. Jnana's RAPID platform additionally enables selective membrane-transporter discovery across autoimmune disease indications.

Competitive Landscape

The PKU and metabolic rare disease landscape is concentrated but opening to novel mechanisms. BH4 cofactors: Kuvan (sapropterin dihydrochloride, BioMarin) — oral, restricted to BH4-responsive PAH variants; generics post 2020 LOE compressing pricing. Enzyme substitution therapy: Palynziq (pegvaliase, BioMarin) — PEGylated PAL, injectable, genotype-agnostic but high immunogenicity and REMS burden. Gene therapy (emerging): BMN 307 (BioMarin, AAV5-PAH — on clinical hold for preclinical carcinogenicity signal), HMI-102/103 (Homology Medicines AAV gene therapy — discontinued 2023), PTC-923/sepiapterin (PTC Therapeutics, oral synthetic BH4 precursor — positive Phase 3 APHENITY 2024). mRNA platform: HMI-103 and earlier PKU mRNA programs (Moderna/Generation Bio) mostly deprioritized. Transporter modulators: JNT-517 (Jnana/Otsuka, oral SLC6A19 allosteric inhibitor) — genotype-agnostic, first-in-class, Phase 1 PoC demonstrated meaningful Phe reduction, advancing to registrational 2025. JNT-517's positioning is oral convenience, no dietary coupling, and no genotype restriction — combining the usability of Kuvan with the breadth of Palynziq, without injection or immunogenicity.